Evidence map›Paper›PMID 34342366›Full record

ArticleTransfusion2021

Comparability of six different immunoassays measuring SARS-CoV-2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction.

Abigail Lamikanra, Dung Nguyen, Peter Simmonds, Sarah Williams, Emma M Bentley, Cathy Rowe, Ashley David Otter, Tim Brooks, Kimberly Gilmour, Annabelle Mai and 12 more

Open access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 1 country.

Abigail LamikanraClinical, Research and Development Departments, NHS Blood and Transplant, Oxford, UK.
Dung NguyenNuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.
Peter SimmondsNuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.ORCID 0000-0002-7964-4700
Sarah WilliamsNuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.
Emma M BentleyNational Institute for Biological Standards and Control (NIBSC), South Mimms, UK.
Cathy RoweRare and Imported Pathogens Laboratory, Public Health England, Porton Down, UK.
Ashley David OtterRare and Imported Pathogens Laboratory, Public Health England, Porton Down, UK.
Tim BrooksRare and Imported Pathogens Laboratory, Public Health England, Porton Down, UK.
Kimberly GilmourLaboratory Services and NIHR BRC Departments, Great Ormond Street Hospital, London, UK.
Annabelle MaiLaboratory Services and NIHR BRC Departments, Great Ormond Street Hospital, London, UK.
Jusvinder DadhraLaboratory Services and NIHR BRC Departments, Great Ormond Street Hospital, London, UK.
Mabel CsatariLaboratory Services and NIHR BRC Departments, Great Ormond Street Hospital, London, UK.
Sheba ZiyengeNuffield Department of Surgical Sciences and BRC Surgical Theme, University of Oxford, Oxford, UK.
Marta OliveiraNuffield Department of Surgical Sciences and BRC Surgical Theme, University of Oxford, Oxford, UK.
Rutger PloegNuffield Department of Surgical Sciences and BRC Surgical Theme, University of Oxford, Oxford, UK.
Pat TsangClinical, Research and Development Departments, NHS Blood and Transplant, Oxford, UK.
Maria ZambonVirology Reference Department, National Infection Service, Public Health England, London, UK.
Robin GopalHigh Containment Microbiology Department, National Infection Service, Public Health England, London, UK.
Julie Huiyuan XiaoMRC Human Immunology Unit, MRC Weatherall Institute, Radcliffe Department of Medicine, John Radcliffe Hospital, Oxford, UK.
Alain TownsendMRC Human Immunology Unit, MRC Weatherall Institute, Radcliffe Department of Medicine, John Radcliffe Hospital, Oxford, UK.
David RobertsClinical, Research and Development Departments, NHS Blood and Transplant, Oxford, UK.
Heli HarvalaMicrobiology Services, NHS Blood and Transplant, London, UK.ORCID 0000-0001-9154-4190
NHS Blood and Transplant · GBPublic Health England · GBGreat Ormond Street Hospital · GBUniversity of Oxford · GBJohn Radcliffe Hospital · GBNational Institute for Biological Standards and Control · GBNuffield Orthopaedic Centre · GB

Funding

COV19-RECPLAS and European Commission H2020 grant: Support-E 101015756National Institutes for Health Research
6 · The paper itself

Abstract

backgroundConvalescent plasma (CP) therapy for coronavirus disease (COVID-19) provides virus-neutralizing antibodies that may ameliorate the outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. The effectiveness of CP likely depends on its antiviral neutralizing potency and is determined using in vitro neutralizing antibody assays. STUDY DESIGN AND

methodsWe evaluated abilities of three immunoassays for anti-spike antibodies (EUROimmun, Ortho, Roche), a pseudotype-based neutralization assay, and two assays that quantify ACE2 binding of spike protein (GenScript and hemagglutination test [HAT]-based assay) to predict neutralizing antibody titers in 113 CP donations. Assay outputs were analyzed through linear regression and calculation of sensitivities and specificities by receiver operator characteristic (ROC) analysis.

resultsMedian values of plasma samples containing neutralizing antibodies produced conversion factors for assay unitage of ×6.5 (pseudotype), ×19 (GenScript), ×3.4 (HAT assay), ×0.08 (EUROimmun), ×1.64 (Roche), and ×0.10 (Ortho). All selected assays were sufficient in identifying the high titer donations based on ROC analysis; area over curve ranged from 91.7% for HAT and GenScript assay to 95.6% for pseudotype assay. However, their ability to predict the actual neutralizing antibody levels varied substantially as shown by linear regression correlation values (from 0.27 for Ortho to 0.61 for pseudotype assay). DISCUSSION: Overall, the study data demonstrate that all selected assays were effective in identifying donations with high neutralizing antibody levels and are potentially suitable as surrogate assays for donation selection for CP therapy.

Indexed as

Antibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 Serological TestingCOVID-19 SerotherapyHumansImmunization, PassiveImmunoassayNeutralization TestsSARS-CoV-2Antibodies, NeutralizingAntibodies, Viralinfectious disease testingintravenous immunoglobulin

Identifiers

PMID34342366
PMCPMC8447482
OpenAlexW3188307788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.